This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2023 Nov 28;330(20):1954-1955.

doi: 10.1001/jama.2023.22465.

Immunotherapy for Nasopharyngeal Carcinoma: The Earlier the Better

Paolo Bossi^{1

2}, Cristina Gurizzan³, Anthony Chan⁴

Affiliations

Affiliations

¹ Department of Biomedical Sciences, IRCCS Humanitas Research Hospital, Milan, Italy.
² IRCCS Humanitas Research Hospital, Milan, Italy.
³ Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University of Brescia, ASST-Spedali Civili, Brescia, Italy.
⁴ State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong, Special Administrative Region, People's Republic of China.

PMID: 38015229
DOI: 10.1001/jama.2023.22465

Editorial

Immunotherapy for Nasopharyngeal Carcinoma: The Earlier the Better

Paolo Bossi et al. JAMA. 2023.

. 2023 Nov 28;330(20):1954-1955.

doi: 10.1001/jama.2023.22465.

Authors

Paolo Bossi^{1

2}, Cristina Gurizzan³, Anthony Chan⁴

Affiliations

¹ Department of Biomedical Sciences, IRCCS Humanitas Research Hospital, Milan, Italy.
² IRCCS Humanitas Research Hospital, Milan, Italy.
³ Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University of Brescia, ASST-Spedali Civili, Brescia, Italy.
⁴ State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong, Special Administrative Region, People's Republic of China.

PMID: 38015229
DOI: 10.1001/jama.2023.22465

No abstract available

PubMed Disclaimer

Comment on

Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi Y, Jin F, Xu R, Pan J, Qu S, Li P, Hu C, Liu YC, Jiang Y, He X, Wang HM, Lim WT, Liao W, He X, Chen X, Wang S, Yuan X, Li Q, Lin X, Jing S, Chen Y, Lu Y, Hsieh CY, Yang MH, Yen CJ, Samol J, Luo X, Wang X, Tang X, Feng H, Yao S, Keegan P, Xu RH. Mai HQ, et al. JAMA. 2023 Nov 28;330(20):1961-1970. doi: 10.1001/jama.2023.20181. JAMA. 2023. PMID: 38015220 Free PMC article. Clinical Trial.

Similar articles

FDA approves first immunotherapy drug for nasopharyngeal carcinoma.
Nierengarten MB. Nierengarten MB. Cancer. 2024 Jun 1;130(11):1903. doi: 10.1002/cncr.35346. Cancer. 2024. PMID: 38757625 No abstract available.
Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
Finazzi T, Rordorf T, Ikenberg K, Huber GF, Guckenberger M, Garcia Schueler HI. Finazzi T, et al. BMC Cancer. 2018 Apr 6;18(1):395. doi: 10.1186/s12885-018-4295-8. BMC Cancer. 2018. PMID: 29625593 Free PMC article.
Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma.
Liang R, Yang L, Zhu X. Liang R, et al. Cancer Control. 2021 Jan-Dec;28:1073274821989301. doi: 10.1177/1073274821989301. Cancer Control. 2021. PMID: 33504193 Free PMC article. Review.
Letter to the Editor, "Immunochemotherapy alone or immunochemotherapy plus subsequent locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma".
Dharmalingam Jothinathan MK. Dharmalingam Jothinathan MK. Oral Oncol. 2024 Sep;156:106948. doi: 10.1016/j.oraloncology.2024.106948. Epub 2024 Jul 13. Oral Oncol. 2024. PMID: 39004023 No abstract available.
Induction treatment prior to chemoradiotherapy in nasopharyngeal carcinoma: triplet or doublet chemotherapy?
Hennessy MA, Morris PG. Hennessy MA, et al. Anticancer Drugs. 2020 Feb;31(2):97-100. doi: 10.1097/CAD.0000000000000867. Anticancer Drugs. 2020. PMID: 31815764 Review.

See all similar articles

Cited by

Exploring cellular diversity in lung adenocarcinoma epithelium: Advancing prognostic methods and immunotherapeutic strategies.
Zhang L, Cui Y, Mei J, Zhang Z, Zhang P. Zhang L, et al. Cell Prolif. 2024 Nov;57(11):e13703. doi: 10.1111/cpr.13703. Epub 2024 Jun 30. Cell Prolif. 2024. PMID: 38946232 Free PMC article.
Targeted Nanoparticle-Based Therapies for Nasopharyngeal Carcinoma: Enhancing Radiosensitization, Photothermal Therapy, and Diagnostics.
Wang T, Wu H, Wang L, Lou N, Guo L. Wang T, et al. Int J Nanomedicine. 2025 May 30;20:7021-7035. doi: 10.2147/IJN.S523213. eCollection 2025. Int J Nanomedicine. 2025. PMID: 40470111 Free PMC article. Review.
Specific Immune Responses and Oncolytic Effects Induced by EBV LMP2A-Armed Modified Ankara-Vaccinia Virus Vectored Vaccines in Nasopharyngeal Cancer.
Sun L, Liu C, Peng J. Sun L, et al. Pharmaceutics. 2025 Jan 3;17(1):52. doi: 10.3390/pharmaceutics17010052. Pharmaceutics. 2025. PMID: 39861700 Free PMC article.
A Review of Immunotherapy for Head and Neck Cancer.
Goetz JW, Rabinowits G, Kalman N, Villa A. Goetz JW, et al. J Dent Res. 2024 Nov;103(12):1185-1196. doi: 10.1177/00220345241271992. Epub 2024 Oct 6. J Dent Res. 2024. PMID: 39370694 Review.
Network pharmacology mechanisms and experimental verification of Hedyotis Diffusae Herba-Scutellariae Barbatae Herba drug pair extract in the treatment of nasopharyngeal carcinoma.
Li T, Chen H, Zhang J, Liu J, Tang R, Zhang L, Feng T, Xiao Y, Liu S, Chen X. Li T, et al. Front Oncol. 2025 Jun 18;15:1601725. doi: 10.3389/fonc.2025.1601725. eCollection 2025. Front Oncol. 2025. PMID: 40607002 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems